Vaccination with sarkosyl insoluble phf-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: A pilot study

Journal of Alzheimer's Disease

Volumn 40, Issue S1, 2014, Pages

  Ando, Kunie ^a,b,c   Kabova, Anna ^a   Stygelbout, Virginie ^a   Leroy, Karelle ^a   Heraud, Céline ^a   Frédérick, Christelle ^a   Suain, Valérie ^a   Yilmaz, Zehra ^a   Authelet, Michèle ^a   Dedecker, Robert ^a   Potier, Marie Claude ^c   Duyckaerts, Charles ^b,c   Brion, Jean Pierre ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CNRS   (France)

Author keywords

Alzheimer's disease; neurofibrillary tangles; paired helical filaments tau; tau vaccination

Indexed keywords

PEPTIDE VACCINE; SARKOSYL INSOLUBLE PAIRED HELICAL FILAMENT TAU VACCINE; TAU PROTEIN; THY ANTIGEN; UNCLASSIFIED DRUG; SARCOSINE; SARKOSYL;

ACTIVE IMMUNIZATION; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PAIRED HELICAL FILAMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VACCINATION; VERY ELDERLY; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE;

AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; NEURONS; PILOT PROJECTS; SARCOSINE; TAU PROTEINS; VACCINATION;

EID: 84901784841     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132237     Document Type: Article

References (45)

1. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177. (Pubitemid 29327547)
2. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 281, 39413-39423. (Pubitemid 46041901)
3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G,Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985. (Pubitemid 32101645)
4. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982. (Pubitemid 32101644)
5. Check E (2002) Nerve inflammation halts trial for Alzheimer's drug. Nature 415, 462. (Pubitemid 34130572)
6. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
7. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99, 6364-6369. (Pubitemid 34493317)
8. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS (2006) Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 175, 541-546. (Pubitemid 44790607)
9. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754. (Pubitemid 46717684)
10. Leroy K, Ando K, Laporte V, Dedecker R, Suain V, Authelet M, Heraud C, Pierrot N,Yilmaz Z, Octave JN, Brion JP (2012) Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am J Pathol 181, 1928-1940.
11. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63, 1459-1467. (Pubitemid 44547559)
12. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27, 9115-9129. (Pubitemid 47312068)
13. Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30, 16559-16566.
14. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224, 472-485.
15. Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr Alzheimer Res 9, 397-405.
16. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tautargeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoSONE 6, e26860.
17. Chai X,Wu S, Murray TK, KinleyR, CellaCV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, CitronM (2011) Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem 286, 34457-34467.
18. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phosphotau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118, 658-667.
19. d'Abramo C, Acker CM, Jimenez HT, Davies P (2013) Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS ONE 8, e62402.
20. Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80, 402-414.
21. Hanger DP, Anderton BH, NobleW(2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
22. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95-130.
23. Ksiezak-Reding H, Binder LI, Yen SH (1990) Alzheimer disease proteins (A68) share epitopes with tau but show distinct biochemical properties. J Neurosci Res 25, 420-430. (Pubitemid 20136593)
24. Brion JP, Hanger DP, Couck AM, Anderton BH (1991) A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities. Biochem J 279(Pt 3), 831-836.
25. Lee VM, Balin BJ, Otvos L, Jr, Trojanowski JQ (1991) A68: A major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251, 675-678. (Pubitemid 21916893)
26. Greenberg SG, Davies P, Schein JD, Binder LI (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem 267, 564-569.
27. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616. (Pubitemid 44156317)
28. Rosenmann H (2013) Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 10, 217-228.
29. Greenberg SG, Davies P (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 87, 5827-5831.
30. Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178, 803-816.
31. Brion JP, Hanger DP, BruceMT, Couck AM, Flament-Durand J, Anderton BH (1991) Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J 273(Pt 1), 127-133.
32. Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM (1994) Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res 39, 669-673.
33. Jicha GA, Berenfeld B, Davies P (1999) Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J Neurosci Res 55, 713-723. (Pubitemid 29173485)
34. Leroy K, Bretteville A, Schindowski K, Gilissen E, Authelet M, De Decker R, Yilmaz Z, Buee L, Brion JP (2007) Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol 171, 976-992. (Pubitemid 47440995)
35. Matsuo ES, Shin RW, Billingsley ML, Van deVoorde A, O'Connor M, Trojanowski JQ, Lee VM (1994) Biopsyderived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13, 989-1002. (Pubitemid 24347311)
36. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71, 2465-2476. (Pubitemid 28531257)
37. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubuleassociated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
38. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248C, 451-456.
39. Kool M, Soullie T, van Nimwegen M,Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN (2008) Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 205, 869-882. (Pubitemid 351549884)
40. Frost B, Diamond MI (2010) Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11, 155-159.
41. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2, 700.
42. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE (2013) Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem 288, 1856-1870.
43. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, Jucker M, Goedert M, Tolnay M(2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11, 909-913.
44. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VMY (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neurosci 33, 1024-1037.
45. Gu J, Congdon EE, Sigurdsson EM (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau protein pathology. J Biol Chem 288, 33081-33095.